Early CVD disease
We search for stratigies to prevent early CVD disease. In Norway, there are currently no organized system to find and inform people at high risk. Previously, a health check was offered persons at the age of 40. This system was discontinued in 2003. Those at risk for early disease will not have symptoms that give them a reason to seek medical advice.
When it comes to premature CVD there are large social inequalities in Norway. People with knowledge are more prone to be checked than people without knowledge. In collaboration with others we seek to develope cost-benefit analysis related to different strategies of detecting high risk persons to prevent early disease.
Familial Hypercholesterolemia (FH) is a distinct monogenetic disorder understood at a molecular level. There are about 15.000 persons with FH in Norway but only 5.000 are diagnosed with genetic testing. A unknown number of patients have thus yet not been offered effective treatment.
Untreated approximately half of the men and women will experience their first myocardial infarction at age 50 and 60, respectively. However, it is not known how modern treatment affect their life-expectancy. No placebo-controlled trials can be performed due to ethical consideration. In Norway, data from several health registers in can be linked to provide reliable data on this topic. Such data will be used to study mortality, morbidity and use of medication in this patient group.